ABSTRACT Although intravenous chlorpheniramine can cause bronchodilatation, oral and parenteral antihistamines have not proved useful in treating asthma. Inhaled antihistamines may cause throat irritation, but a recent study of the antihistamine, clemastine, showed it to be an effective bronchodilator without irritant effects. We have extended these studies to determine the site of action of inhaled clemastine and to assess its potential usefulness both as a bronchodilator and as a maintenance treatment. Eleven stable asthmatic patients received inhaled clemastine and placebo and the effect was assessed by serial maximum expiratory flow volume (MEFV) curves breathing air and a helium/oxygen (He/02) mixture. There was no significant improvement in peak flow rates during air breathing after clemastine and no significant difference between the responses to drug and placebo. Minor but significant changes were seen in some flow measurements on the downslope of the MEFV curve during air and He/02 breathing, and these are tentatively ascribed to a dilating effect of clemastine on peripheral airways where flow is laminar. Subsequent administration of inhaled isoprenaline showed the patients to be still capable of significant bronchodilatation. The addition of clemastine, from a pressurised aerosol, to the patients' therapeutic regimen for two weeks was no more effective than placebo in controlling airflow obstruction, and did not reduce the need for standard bronchodilators. In our patients clemastine was not a clinically useful bronchodilator either acutely or as a maintenance treatment for asthma.
In asthmatic patients the bronchial smooth muscle is hyperreactive to histamine released by allergic reactions, but oral and parenteral antihistamine have not proved useful in treating asthma, although intravenous chlorpheniramine can produce bronchodilatation (Popa, 1977) . Aerosols of antihistamine may cause throat irritation, but a recent study of the H1-receptor blocking antihistamine, clemastine, showed it to have no irritant effects when inhaled. In a double-blind study 12 patients (six atopic) who had recovered from acute severe asthma were given 1 ml clemastine 005% in saline, salbutamol 0 05%, or physiological saline by aerosol inhalation. Both clemastine and salbutamol caused significant bronchodilatation, and there was no significant difference between them. Subsequent work (Nogrady and Bevan, 1 978) has confirmed that the bronchodilator properties of clemastine are not related to any anticholinergic action.
We have extended these studies to determine the site of action of inhaled clemastine and to assess its potency, both acutely and as a maintenance treatment.
Methods

NORMAL SUBJECTS
Three normal subjects inhaled 0f2 mg clemastine or physiological saline placebo from a pressurised aerosol and had serial measurements of airways resistance and total lung capacity measured in the body plethysmograph for two hours after administration of drug (Despas et al, 1972) . Initial studies showed that even with quite severe airflow obstruction three minutes He/O2 breathing was sufficient for end-tidal nitrogen concentration to be less than 5% when measured with a mass spectrometer. Recordings during air breathing were made at -15, -5, +5, +15, +30, +45, +60, +90, and +120 minutes with inhalation of drug or placebo at zero time, and He/02 measurements were made in addition at -15. -5, +30, +60, and +120 minutes. Nine patients received 2 ml 0-05% clemastine in saline or 2 ml physiological saline, in double-blind fashion and randomised order via an air-driven Wright nebuliser. was significantly higher after drug than placebo at 120 minutes but at no other time. Vmaxo was significantly higher after drug than placebo at 60 minutes but at no other time. There were no significant placebo-drug differences for Vmax25.
After isoprenaline inhalation there was a significant increase in all flow rates both on drug and placebo days whether breathing air or the He/02 mixture (figs 1 and 2). It appeared to have no effect on the degree of density dependence of flow as judged by PFR and Vmax50. Using values for Vmax25, however, the response to He/02 breathing (defined as the percentage increase in flow on He/02 breathing) was significantly greater after isoprenaline than before (P<0-01) (fig 3) . MAINTENANCE STUDY In the maintenance treatment studies the mean variability of the air flow obstruction in each of the six asthmatic patients during the last 10 days of both drug and placebo periods ranged from 10.1-36.4% (mean 19-017-7). The mean morning peak flow rates during the placebo period were 295+138 and during the clemastine period 294:+± 132. The results at 2200 for PFRs were 345+153 during placebo and 352+147 during the clemastine period. Analysis of the individual results showed no statistical differences between the treatment or placebo periods either as judged by PFR and variability or by symptom score and number of dosages of bronchodilator required.
Discussion
Despite using a dose of inhaled antihistamine twice as large as that used previously we have been unable to show that clemastine was a useful bronchodilator in our patients. Serial PFRs breathing air showed no improvement after inhalation of the drug. A minor but significant effect, however, has been observed on some of the flow variables which (for the following reasons) we suggest may have been due to a minor degree of small airway dilatation. Flow limitation in small airways reduces flow rates at low lung volumes more than at high and mid-lung volumes (Bass, 1973) . In our patients Vmax25 and Vmax50 breathing air improved significantly after clemastine but without a corresponding improvement in PFR. This would be consistent with some reduction in small airway flow limitation after the drug. This suggestion may be corroborated by the flow rate response to He/02 breathing. Improvement of flow rates during He/02 breathing has been attributed (Despas et al, 1972) to the major site of flow limitation being in larger airways with low total cross-sectional area and a density-dependent flow regimen due to turbulent flow and convective acceleration. Absence of response is attributed to obstruction principally in small peripheral airways with large total cross-sectional area and laminar flow. Thus an increase in the response to He/02 breathing after therapeutic intervention would suggest a shift of the major site of airflow limitation away from the small airways towards the larger airways where a turbulent (density dependent) flow regimen predominates. In our patients more significant increases in PFR, Vmax50, and Vmax25 occurred on He/02 breathing than during air-breathing after the inhalation of clemastine. Thus although clemastine had a minor overall effect in our patients some small airway dilatation may have occurred.
The reasons for the differences between this and the previous study are not clear. Their patients had recovered to a relatively stable condition from an episode of severe asthma, while most of our subjects were relatively stable outpatients, although still capable of significant bronchodilatation as judged by their response to isoprenaline (figs 1 and 2). Age and atopic state were similar in both studies, and although concurrent treatment is not mentioned in their report, it seems likely that if their patients were recovering from an acute episode of asthma more could have been taking oral steroids than the few who were in our group. Their patients were studied in the morning when spontaneous diurnal improvement may be expected, and a prominent placebo response was recorded. While mean percentage changes for the whole group were statistically better during the period of observation after clemastine than after placebo, they did not comment on their table of individual baseline and peak values of FEV1 and PFR after clemastine and placebo, which shows individual maximal responses as opposed to mean changes with time. Analysis of those figures suggest that maximal values after clemastine were greater than placebo in only eight of 12 patients and in some only slightly greater.
Moreover, we find it impossible to reconcile in their table 2 a baseline to peak mean percentage change after placebo of 27.9% with, in their table 1 and fig 1, a mean maximal change of only 15% at any given time. In their studies clemastine appeared to have a later onset of action than salbutamol and duration of action was probably longer, and for this reason we assessed the value of clemastine as a maintenance treatment when delivered from a pressurised aerosol. The dosage chosen (0.2 mg) is a reasonable extrapolation for a pressurised 775 aerosol dosage compared with the 0O5 mg thought to be effective via a nebuliser . (Compare salbutamol 200-400 ,ug from a pressurised aerosol and 2 5-5 mg from a wet nebuliser). The results from our maintenance treatment trial may be criticised because of the continuation of other treatments (beclomethasone+ioral corticosteroids) but in view of our disappointing results in the acute study it was not thought to be ethically justified to withhold the other treatments. In only one patient, however, did the peak flow rate at any time approach the predicted normal value, and the mean variability of 19% suggests that there was adequate scope for further improvement with clemastine, but this did not occur.
The proportion of our asthmatic patients with 20% increased flow rates on He/02 breathing was similar to that reported previously in stable asthmatic patients (Chan-Yeung et al, 1976; Wellman et al, 1976) . The relation, however, between degree of airflow obstruction and presence of He/02 response was not so evident.
Isoprenaline inhalation was associated with significant increases in flow rates at all lung volumes and a significant improvement in vital capacity. Ingram et al (1977) showed that in normal subjects isoprenaline appears to dilate preferentially small peripheral airways, and work from the same laboratory (Wellman et al, 1976) suggested that the same is true for patients with airflow obstruction, and that the degree of response to bronchodilators correlates with the presence of increased density dependence of flow after bronchodilators. Despite the fact that our patients all exhibited a pronounced bronchodilator response to isoprenaline the degree of increased density dependence of flow after isoprenaline was not significant for Vmax50, suggesting that although isoprenaline may preferentially dilate small airways, it must have a significant effect on large airways as well.
The use of t-tests in this study may be criticised because with small numbers it is impossible to be sure that the data is normally distributed. We repeated the analysis with the sign test (Geigy Scientific Tables, 1970) , which is distribution-free but less powerful than the t-test, and found that eight fewer marked points in figs 1 and 2 attained significance at the 5% level, and there were then no significant drug-placebo differences. Thus our arguments above are unaltered.
Comparison of studies such as these made on different days may be difficult because the lability of asthma causes baseline measurements to vary. It is then more logical to use the values after maximal bronchodilatation as the standard for normalisation, since they should show less variability, as they did in this study. Baseline predrug measurements thus adjusted were not significantly different on the two days, with the single exception of Vmax50 on He/02. We conclude that in our patients clemastine when given by the inhaled route did not prove to be a clinically effective bronchodilator, and neither has it been shown to be of value as a maintenance treatment in asthma. 
